Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CT-004
- Development stage
- Preclinical
- Lead developer
- Coagulant Therapeutics
01
Overview
CT-004 is an investigational therapeutic candidate being developed by Coagulant Therapeutics, currently in the IND-enabling phase of development. Coagulant Therapeutics focuses on the design of therapies for acute bleeding and coagulation-related conditions, utilizing platforms such as engineered coagulation factors and nanobodies. As of early 2024, specific information regarding the molecular target, modality, and primary indication for CT-004 has not been publicly disclosed by the developer, although it is positioned within a pipeline targeting severe hemorrhage and hematological disorders.
Beyond the preview
Go deeper on CT-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CT-004.